Literature DB >> 19809412

Efficacy of three different dosages of esomeprazole in the long-term management of reflux disease: a prospective, randomized study, using the wireless Bravo pH system.

Konstantinos V Vasiliadis1, Nikos Viazis, Jiannis Vlachogiannakos, Spiros N Sgouros, Gerasimos Stefanidis, Athanasios Archimandritis, Dimitrios G Karamanolis.   

Abstract

OBJECTIVES: Gastroesophageal reflux disease (GERD) is a chronic condition that usually requires long-term maintenance therapy with proton-pump inhibitors (PPIs). In clinical practice, patients receive PPIs at the lowest dose to control symptoms. However, it is not known whether this approach adequately controls acidic esophageal reflux. We sought to investigate the efficacy of three different dosages of esomeprazole in patients receiving maintenance therapy for GERD, using the Bravo pH system.
METHODS: Patients with a previous history of erosive esophagitis A or B (LA classification) that was healed at the time of enrollment or endoscopy-negative reflux disease (ENRD), documented with an abnormal pH study, were randomized to receive maintenance therapy with esomeprazole 40 mg twice daily (group A), once daily (group B), or every other day (group C). Intraesophageal pH was monitored for two consecutive days using the Bravo wireless system, 30 days after randomization. The parameters subjected to analysis were percent of total time pH<4 and the De Meester score.
RESULTS: The pH results from 73 patients (group A=24, group B=24, group C=25 patients) were subjected to final analysis. On the first day of the study, the mean (+/-s.d.) percent of total time pH <4 and the De Meester score were group A: 0.9(1.2) and 4.1(4.0); group B: 1.5(1.6) and 7.0(6.9); group C: 1.3(1.0) and 6.0(3.3), respectively (P=0.262 and 0.134, respectively). On the second day of the study, the corresponding values were group A: 0.7(1.0) and 3.9(5.9); group B: 1.5(1.8) and 6.4(6.6); group C: 7.0(4.4) and 29.4(19.4), respectively. The difference was statistically significant (P<0.0001 and <0.0001, respectively). Further analysis showed that patients not receiving PPI had a significantly higher mean percent of total time pH<4 and De Meester score as compared with patients on PPI once or twice daily (P<0.001 and <0.001 respectively).
CONCLUSIONS: The administration of esomeprazole 40 mg every other day does not control acidic esophageal reflux on the day off PPI. Esomeprazole 40 mg once daily effectively controls reflux of acid in patients with history of mild esophagitis or ENRD, whereas doubling the dose does not seem to confer any further advantage.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19809412     DOI: 10.1038/ajg.2009.556

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

Review 1.  Proton Pump Inhibitors in Gastroesophageal Reflux Disease: Friend or Foe.

Authors:  C Prakash Gyawali
Journal:  Curr Gastroenterol Rep       Date:  2017-09

2.  Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency.

Authors:  David Y Graham; Aylin Tansel
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-28       Impact factor: 11.382

3.  Efficacy of different endoscopic treatments in patients with gastroesophageal reflux disease: a systematic review and network meta-analysis.

Authors:  Peiwei Xie; Jing Yan; Ling Ye; Chong Wang; Yuanyuan Li; Youxiang Chen; Guohua Li
Journal:  Surg Endosc       Date:  2021-03-01       Impact factor: 3.453

Review 4.  A Meta-Analysis and Systematic Review of the Efficacy of Twice Daily PPIs versus Once Daily for Treatment of Gastroesophageal Reflux Disease.

Authors:  Hongying Zhang; Zhiping Yang; Zhen Ni; Yongquan Shi
Journal:  Gastroenterol Res Pract       Date:  2017-08-22       Impact factor: 2.260

5.  Comparison of health care resource utilization and costs among patients with GERD on once-daily or twice-daily proton pump inhibitor therapy.

Authors:  Reema Mody; Debra Eisenberg; Likun Hou; Siddhesh Kamat; Joseph Singer; Lauren B Gerson
Journal:  Clinicoecon Outcomes Res       Date:  2013-04-22

Review 6.  Use of Mobile Devices to Measure Outcomes in Clinical Research, 2010-2016: A Systematic Literature Review.

Authors:  Brian Perry; Will Herrington; Jennifer C Goldsack; Cheryl A Grandinetti; Kaveeta P Vasisht; Martin J Landray; Lauren Bataille; Robert A DiCicco; Corey Bradley; Ashish Narayan; Elektra J Papadopoulos; Nirav Sheth; Ken Skodacek; Komathi Stem; Theresa V Strong; Marc K Walton; Amy Corneli
Journal:  Digit Biomark       Date:  2018-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.